186 related articles for article (PubMed ID: 24433532)
1. A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Hompes D; Aalbers A; Boot H; van Velthuysen ML; Vogel W; Prevoo W; van Tinteren H; Verwaal V
Colorectal Dis; 2014 Aug; 16(8):O264-72. PubMed ID: 24433532
[TBL] [Abstract][Full Text] [Related]
2. Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.
Hompes D; Boot H; van Tinteren H; Verwaal V
J Surg Oncol; 2011 Sep; 104(3):269-73. PubMed ID: 21465492
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
[TBL] [Abstract][Full Text] [Related]
6. Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Ishida H; Kumamoto K; Ishibashi K; Hatano S; Matsuzawa T; Okada N; Kumagai Y; Baba H; Haga N
Tech Coloproctol; 2013 Dec; 17(6):647-52. PubMed ID: 23389285
[TBL] [Abstract][Full Text] [Related]
7. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
[TBL] [Abstract][Full Text] [Related]
8. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
11. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.
Zani S; Papalezova K; Stinnett S; Tyler D; Hsu D; Blazer DG
J Surg Oncol; 2013 Mar; 107(4):307-11. PubMed ID: 22811275
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
Klaver YL; Simkens LH; Lemmens VE; Koopman M; Teerenstra S; Bleichrodt RP; de Hingh IH; Punt CJ
Eur J Surg Oncol; 2012 Jul; 38(7):617-23. PubMed ID: 22572106
[TBL] [Abstract][Full Text] [Related]
15. Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer.
Turner KM; Hanna NN; Zhu Y; Jain A; Kesmodel SB; Switzer RA; Taylor LM; Richard Alexander H
Ann Surg Oncol; 2013 Apr; 20(4):1068-73. PubMed ID: 23456383
[TBL] [Abstract][Full Text] [Related]
16. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
[TBL] [Abstract][Full Text] [Related]
18. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Klaver YL; de Hingh IH; Boot H; Verwaal VJ
J Surg Oncol; 2011 Apr; 103(5):431-4. PubMed ID: 21400529
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy with bevacizumab.
Gruenberger T; Gruenberger B; Scheithauer W
J Clin Oncol; 2006 Jun; 24(16):2592-3; author reply 2593-4. PubMed ID: 16735714
[No Abstract] [Full Text] [Related]
20. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
